Literature DB >> 11815569

Increased in vitro activity of the novel des-fluoro(6) quinolone BMS-284756 against genetically defined clinical isolates of Staphylococcus aureus.

Franz-Josef Schmitz1, Mechthild Boos, Susanne Mayer, Harold Jagusch, Ad C Fluit.   

Abstract

The in vitro activities of the novel des-fluoro(6) quinolone BMS-284756, ciprofloxacin, gatifloxacin and moxifloxacin were tested against 248 genetically defined Staphylococcus aureus isolates, comprised of 116 unrelated S. aureus, seven heterogeneous vancomycin-intermediate S. aureus (hetero-VISA) strains and 125 clonally related MRSA. All strains were susceptible to BMS-284756 at an investigational breakpoint of 1 mg/L. Reserpine did not decrease the MIC of BMS-284756 in any of the strains tested. The novel des-fluoro(6) quinolone BMS-284756 showed a significantly increased anti-staphylococcal activity.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 11815569     DOI： 10.1093/jac/49.2.283

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN： 0305-7453            Impact factor:   5.790


  2 in total

1.  Mutant prevention concentration of garenoxacin (BMS-284756) for ciprofloxacin-susceptible or -resistant Staphylococcus aureus.

Authors:  Xilin Zhao; William Eisner; Nathan Perl-Rosenthal; Barry Kreiswirth; Karl Drlica
Journal:  Antimicrob Agents Chemother       Date:  2003-03       Impact factor: 5.191

2.  Antimicrobial activities of garenoxacin (BMS 284756) against Asia-Pacific region clinical isolates from the SENTRY program, 1999 to 2001.

Authors:  K J Christiansen; J M Bell; J D Turnidge; R N Jones
Journal:  Antimicrob Agents Chemother       Date:  2004-06       Impact factor: 5.191
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.